Barclays
KLRS

Barclays’s Kalaris Therapeutics KLRS Stock Holding History

Barclays’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.5K Sell
5,280
-785
-13% -$6.97K ﹤0.01% 4471
2025
Q4 		$51.2K Buy
+6,065
New +$38.8K ﹤0.01% 4738
2025
Q2 		– Sell
-1
Closed -$8 – 5639
2025
Q1 		$8 Buy
+1
New +$10 ﹤0.01% 5185
2024
Q2 		– Sell
-1,532
Closed -$26.6K – 5392
2024
Q1 		$26.6K Sell
1,532
-1,496
-49% -$24.4K ﹤0.01% 4721
2023
Q4 		$47.3K Buy
3,028
+2,219
+274% +$87.5K ﹤0.01% 4781
2023
Q3 		$40K Buy
809
+2
+0.2% +$136 ﹤0.01% 3956
2023
Q2 		$63.1K Sell
807
-742
-48% -$70.5K ﹤0.01% 3742
2023
Q1 		$140K Buy
1,549
+323
+26% +$41.1K ﹤0.01% 3990
2022
Q4 		$145K Buy
1,226
+305
+33% +$51.7K ﹤0.01% 4016
2022
Q3 		$167K Sell
921
-2,358
-72% -$367K ﹤0.01% 3304
2022
Q2 		$294K Buy
3,279
+2,435
+289% +$255K ﹤0.01% 3209
2022
Q1 		$131K Buy
+844
New +$168K ﹤0.01% 3665

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Barclays's KLRS Position: Q1 2026 in Review

Barclays reduced its Kalaris Therapeutics (KLRS) stake by 13% in Q1 2026, selling an estimated $6.97K and leaving 5,280 shares worth $30.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4471.

Barclays first reported a position in KLRS in Q1 2022 and has held it in 12 quarters since. The position peaked at $294K in Q2 2022. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Barclays held 5,280 shares of Kalaris Therapeutics worth $30.5K as of Q1 2026.
  • Barclays sold 785 Kalaris Therapeutics shares in Q1 2026, an estimated $6.97K.
  • Kalaris Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4471 holding.
  • Barclays first reported a position in Kalaris Therapeutics in Q1 2022 and has held it in 12 quarters since.
  • Barclays's Kalaris Therapeutics position peaked at $294K in Q2 2022.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.